1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Sage May Be Forced To Simplify Brexanolone Dosing Regimen

 
• By Derrick Gingery

Advisory committee members warned of dosing errors and other potential problems with the titration/taper regimen used in the clinical trials, arguing a simpler dosing schedule also could increase patient access.

Infusion of a hospital

SAGE Therapeutics Inc. may be forced to simplify the dosing regimen for its proposed postpartum depression treatment brexanolone in order to get approval in the US after advisory committee members warned that administration may prove difficult for trained hospital staff.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers